Healthcare Industry News: radiosurgery
News Release - September 26, 2016
Varian Exhibiting New HyperArc Technology for High Definition Radiotherapy and RadiosurgeryPALO ALTO, Calif., Sept. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (VAR) today announced advances in its technology for high definition radiotherapy and radiosurgery. Varian is exhibiting its new HyperArc™ High Definition Radiotherapy (HDRT) technology at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting.
"This exciting new technology unlocks the potential of using highly non-coplanar treatment strategies to usher in a new era of precision in radiotherapy and radiosurgery for cancer patients," said Kolleen Kennedy, president of Varian Oncology Systems. "HyperArc is the first step into our OnComand ecosystem that Varian introduced to the community last year. It is designed to automate and simplify sophisticated treatments such as Stereotactic radiosurgery (SRS), and make them available to more cancer patients around the world."
With HyperArc, clinicians should be able to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue. (See image)
HyperArc is designed to capitalize on the unique capabilities of Varian's TrueBeam™ and EDGE™ treatment platforms including the PerfectPitch™ couch. The HyperArc treatment delivery technology is currently FDA 510(k) pending. Treatment planning supporting HyperArc is a Works in Progress and is being developed to do virtual dry runs to evaluate treatment quality before the dose is delivered.
The company is aiming to make the HyperArc technology clinically available beginning in 2017. First generation HyperArc products will be designed for the radiosurgical treatment of brain metastases, with subsequent products being developed for other treatments throughout the body. Clinicians have been collaborating with Varian on the development and preliminary testing of this technology.
"In the testing we have done to date, we have found that the HyperArc technology showed a significant improvement in both the dose coverage to the targeted tumor and an associated reduction in the dose to the organs at risk," said Garry Currie, head of Radiotherapy Physics at Beatson West of Scotland Cancer Centre in Glasgow, U.K. "We are excited about the potential of this technology and the impact it could make in the fight against cancer."
Approximately 20 percent of newly diagnosed cancer patients will develop brain metastases, and for many SRS is recommended as a primary treatment option. HyperArc is designed to make it possible to easily target and eradicate isolated brain metastases and eliminate the need and complications with whole brain radiation.
The HyperArc technology is being exhibited in the Varian booth (#5063) at ASTRO from September 25-27th.
For more information on HyperArc, visit http://www.varian.com/news/hyperarc
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, cables and connectors as well as image processing software and workstations for use in medical and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 7,700 people who are located at manufacturing sites in North America, Europe, and China and sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry or market outlook; the ability of the company's products to treat cancer or achieve certain results; and any statements using the terms "should," "will," "improve," "design," "aim" and similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the demand for the company's products; the company's ability to develop, gain regulatory clearance or approval, commercialize, and deploy new and existing products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsVarian and Tata Trusts Sign Framework Agreement for Advanced Cancer Care Solutions to Address Growing Need in India
Varian Installs Gantry for ProBeam Compact Proton Therapy System at New Treatment Center in Singapore
First Cancer Patients in Taiwan Treated with Varian HyperArc High-Definition Radiotherapy